211 
DR. FREDRICKSON: We will have your full statement, Mr. Samuels. You 
will provide that for us? 
MR. SAMUELS: All right. 
DR. FREDRICKSON: Thank you. 
MR. SAMUELS: And as for actual inspectors, it is not envisaged by the 
Act that we have a policeman in every laboratory or behind every machine in 
every factory. What you need is a police force that is adequate, not for 
most people, because most people are going to do what those guidelines or 
standards ask them to do, but for the few. I think that with another incre- 
ment of specially trained inspectors, the number of laboratories is not now so 
many that we couldn't cover this. 
DR. FREDRICKSON: Any further comment or question? 
Then we will turn to the next invited witness, who is Dr. John Adams, 
who is Vice President for Scientific and Professional Relations, from the 
Pharmaceutical Manufacturers Association in Washington. 
Dr. Adams. 
DR. ADAMS: Thank you, Dr. Fredrickson, members of the Committee, ladies 
and gentlemen. My purpose in being here this morning to appear before this 
Committee is to repeat the stated policy of the Pharmaceutical Manufacturers 
Association and its member firms relative to recombinant DNA research. We 
have stated that policy on many occas ions--congress ional testimony, formal 
comments to the National Institutes of Health, and on other occasions — and 
essentially that policy remains unchanged with respect to the revision in the 
Guidelines which was proposed on September 27. 
We have, on previous occasions, indicated that our member firms — and 
there are only three at the moment that we are aware of that are engaged in 
such research — will voluntarily comply with the NIH Guidelines. We have 
every reason to believe that that is the case at the present time. We have 
indicated previously that we feel the Guidelines as they were proposed and now 
revised need to be modified in the case of industrial research. The Guide- 
lines, as I think everyone in this room is aware, were written primarily for 
recipients of federally supported research. They were not written for the 
industrial sector, or for that matter, to nongovernment-supported academic 
research. In view of this, some modification is needed. 
I can tell you that our companies are committed to the operative portions 
of those Guidelines, the physical and biological containment provisions, but 
we do feel that there are modifications necessary with respect to the pro- 
tection of industrial property rights. 
We have submitted formal comments on the revision, including some techni- 
cal comments which I will not take the time this morning to discuss. They are 
[ 415 ] 
